With the progress in insulin delivery and glucose monitoring systems, the treatment environment for T1DM patients has been significantly improved; however, the blood glucose control of T1DM patients is still not ideal, and only less than 1/3 patients can achieve the ideal blood glucose control (Miller et al., 2015; Paik and Blair, 2019). This evidence concerns the gene INS and type 1 diabetes mellitus.